Kinase inhibition--a new approach to the treatment of rheumatoid arthritis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.BMC musculoskeletal disorders · 2013
   Pooled it
2. Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.Nature reviews. Drug discovery · 2016
   Review
3. Regulation of Transforming Growth Factor β-Activated Kinase Activation by Epigallocatechin-3-Gallate in Rheumatoid Arthritis Synovial Fibroblasts: Suppression of K(63) -Linked Autoubiquitination of Tumor Necrosis Factor Receptor-Associated Factor 6.Arthritis & rheumatology (Hoboken, N.J.) · 2016
   Article
4. Most Trial Eligibility Criteria and Patient Baseline Characteristics Do Not Modify Treatment Effect in Trials Using Targeted Therapies for Rheumatoid Arthritis: A Meta-Epidemiological Study.PloS one · 2015
   Article
5. Remission of rheumatoid arthritis on brentuximab vedotin.Rheumatology (Oxford, England) · 2014
   Article
6. Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses.The Journal of allergy and clinical immunology · 2014
   Article
7. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.Journal of immunology research · 2014
   Review
8. [Personalized medicine in cytokine-targeted therapy].Zeitschrift fur Rheumatologie · 2013
   Article
9. Anti-inflammatory therapy in chronic disease: challenges and opportunities.Science (New York, N.Y.) · 2013
   Review

Corrections and comments

• Comment on
  Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.2012
• Comment on
  Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as